Sign up
Pharma Capital

Milestone for Futura Medical as it completes recruitment for phase III erectile dysfunction gel

Futura Medical PLC's (LON:FUM) Ken James discusses the completion of recruitment for the first European phase III clinical trial of their fast-acting treatment for erectile dysfunction (ED).

The headline data from the study is expected by the end of the year.

 

View full FUM profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.